Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grail, Inc. stock logo
GRAL
Grail
$38.30
-2.6%
$30.41
$12.33
$63.99
$1.38BN/A1.25 million shs472,196 shs
Illumina, Inc. stock logo
ILMN
Illumina
$80.75
-4.1%
$78.46
$68.70
$156.66
$12.78B1.352.31 million shs957,286 shs
Morgan Stanley stock logo
MS
Morgan Stanley
$126.49
-2.0%
$116.40
$90.94
$142.03
$202.93B1.37.51 million shs1.99 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grail, Inc. stock logo
GRAL
Grail
+2.85%-8.32%+45.63%-25.25%+3,931,999,900.00%
Illumina, Inc. stock logo
ILMN
Illumina
+1.52%+4.87%+18.25%-18.23%-22.41%
Morgan Stanley stock logo
MS
Morgan Stanley
-1.30%-0.20%+18.34%-8.27%+28.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Grail, Inc. stock logo
GRAL
Grail
0.79 of 5 stars
1.12.00.00.04.10.80.6
Illumina, Inc. stock logo
ILMN
Illumina
4.8208 of 5 stars
4.23.00.04.23.43.31.3
Morgan Stanley stock logo
MS
Morgan Stanley
4.4496 of 5 stars
2.13.04.22.41.92.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Grail, Inc. stock logo
GRAL
Grail
2.25
Hold$31.50-17.75% Downside
Illumina, Inc. stock logo
ILMN
Illumina
2.48
Hold$128.1558.70% Upside
Morgan Stanley stock logo
MS
Morgan Stanley
2.29
Hold$132.464.72% Upside

Current Analyst Ratings Breakdown

Latest ILMN, MS, and GRAL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Illumina, Inc. stock logo
ILMN
Illumina
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00
5/15/2025
Illumina, Inc. stock logo
ILMN
Illumina
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$190.00 ➝ $185.00
5/14/2025
Grail, Inc. stock logo
GRAL
Grail
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$32.00 ➝ $43.00
5/12/2025
Illumina, Inc. stock logo
ILMN
Illumina
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$136.00 ➝ $100.00
5/12/2025
Illumina, Inc. stock logo
ILMN
Illumina
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$92.00 ➝ $87.00
5/9/2025
Illumina, Inc. stock logo
ILMN
Illumina
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$120.00 ➝ $85.00
5/9/2025
Illumina, Inc. stock logo
ILMN
Illumina
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $114.00
4/29/2025
Illumina, Inc. stock logo
ILMN
Illumina
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$115.00 ➝ $92.00
4/21/2025
Grail, Inc. stock logo
GRAL
Grail
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$32.00
4/14/2025
Morgan Stanley stock logo
MS
Morgan Stanley
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$125.00 ➝ $122.00
4/14/2025
Morgan Stanley stock logo
MS
Morgan Stanley
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$130.00 ➝ $120.00
(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Grail, Inc. stock logo
GRAL
Grail
$130.71M10.54N/AN/AN/A
Illumina, Inc. stock logo
ILMN
Illumina
$4.34B2.95$3.90 per share20.72$14.98 per share5.39
Morgan Stanley stock logo
MS
Morgan Stanley
$59.92B3.39$7.92 per share15.97$55.58 per share2.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Grail, Inc. stock logo
GRAL
Grail
N/A-$60.99N/AN/AN/AN/AN/AN/AN/A
Illumina, Inc. stock logo
ILMN
Illumina
-$1.22B-$6.07N/A15.651.60-27.95%13.37%5.49%8/5/2025 (Estimated)
Morgan Stanley stock logo
MS
Morgan Stanley
$13.39B$8.5215.9313.411.1812.48%14.39%1.09%7/15/2025 (Estimated)

Latest ILMN, MS, and GRAL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Grail, Inc. stock logo
GRAL
Grail
-$4.03-$3.10+$0.93-$3.10$35.80 million$31.84 million
5/8/2025Q1 2025
Illumina, Inc. stock logo
ILMN
Illumina
$0.96$0.97+$0.01$0.82$1.03 billion$1.04 billion
4/11/2025Q1 2025
Morgan Stanley stock logo
MS
Morgan Stanley
$2.21$2.60+$0.39$2.60$16.81 billion$17.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Grail, Inc. stock logo
GRAL
Grail
N/AN/AN/AN/AN/A
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Morgan Stanley stock logo
MS
Morgan Stanley
$3.702.93%+19.13%43.43%12 Years

Latest ILMN, MS, and GRAL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/11/2025
Morgan Stanley stock logo
MS
Morgan Stanley
quarterly$0.92503.48%4/30/20254/30/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Grail, Inc. stock logo
GRAL
Grail
N/A
9.65
9.65
Illumina, Inc. stock logo
ILMN
Illumina
0.63
1.77
1.42
Morgan Stanley stock logo
MS
Morgan Stanley
3.14
0.80
0.80

Institutional Ownership

CompanyInstitutional Ownership
Grail, Inc. stock logo
GRAL
Grail
N/A
Illumina, Inc. stock logo
ILMN
Illumina
89.42%
Morgan Stanley stock logo
MS
Morgan Stanley
84.19%

Insider Ownership

CompanyInsider Ownership
Grail, Inc. stock logo
GRAL
Grail
1.85%
Illumina, Inc. stock logo
ILMN
Illumina
2.60%
Morgan Stanley stock logo
MS
Morgan Stanley
0.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Grail, Inc. stock logo
GRAL
Grail
1,36035.97 millionN/AOptionable
Illumina, Inc. stock logo
ILMN
Illumina
11,500158.30 million158.13 millionOptionable
Morgan Stanley stock logo
MS
Morgan Stanley
82,4001.60 billion1.61 billionOptionable

Recent News About These Companies

What next for the markets? Here's what the professionals think
Can Sensex hit 1 lakh in 1 year? Morgan Stanley gives new target
$M stock is up 2% today. Here's what we see in our data.
Why Morgan Stanley Remains Bullish On Tesla

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Grail stock logo

Grail NASDAQ:GRAL

$38.30 -1.02 (-2.59%)
As of 01:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Illumina stock logo

Illumina NASDAQ:ILMN

$80.75 -3.46 (-4.11%)
As of 01:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Morgan Stanley stock logo

Morgan Stanley NYSE:MS

$126.49 -2.64 (-2.05%)
As of 01:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.